| Literature DB >> 33029101 |
Kok-Yong Chin1, Chin Yi Chan1, Shaanthana Subramaniam1, Norliza Muhammad1, Ahmad Fairus2, Pei Yuen Ng3, Nor Aini Jamil4, Noorazah Abd Aziz5, Soelaiman Ima-Nirwana1, Norazlina Mohamed1.
Abstract
Objectives: Metabolic syndrome (MetS) is a cluster of metabolic abnormalities that elevates the individual risk of cardiovascular diseases. These abnormalities are also known to alter bone remodelling. Therefore, MetS may be associated with osteoporosis. This study aims to determine the association between MetS and its components and bone mineral density (BMD) assessed by dual-energy X-ray absorptiometry (DXA) among Malaysians.Entities:
Keywords: cholesterol; hypertension; insulin resistance; osteopenia; osteoporosis; triglycerides
Mesh:
Year: 2020 PMID: 33029101 PMCID: PMC7532478 DOI: 10.7150/ijms.49030
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Basic characteristics of the subjects
| Characteristics | Male (n=190) | Female (n=210) | Overall (n=400) |
|---|---|---|---|
| mean (SD) | mean (SD) | mean (SD) | |
| Age (years) | 57.8 (9.6) | 56.1 (8.1) | 56.9 (8.9) |
| Waist circumference (cm) | 88.6 (12.4) | 82.2 (10.5) | 85.2 (11.9) |
| Height (cm) | 167.1 (6.0) | 154.5 (5.4) | 160.5 (8.5) |
| Weight (kg) | 70.8 (11.6) | 60.1 (11.9) | 65.2 (12.9) |
| Body mass index (kg/m2) | 25.3 (3.9) | 25.2 (5.0) | 25.3 (4.5) |
| Spine BMD (g/cm2) | 1.00 (0.16) | 0.90 (0.16) | 0.95 (0.17) |
| Total hip BMD (g/cm2) | 0.93 (0.13) | 0.83 (0.12) | 0.88 (0.14) |
| Fat mass (kg) | 21.0 (6.2) | 24.2 (7.3) | 22.7 (7.0) |
| Lean mass (kg) | 47.0 (6.2) | 33.6 (5.1) | 40.0 (8.8) |
| Fat percentage (%) | 29.6 (4.9) | 40.1 (5.4) | 35.1 (7.4) |
| Systolic blood pressure (mmHg) | 131.9 (18.0) | 126.6 (18.2) | 129.1 (18.3) |
| Diastolic blood pressure (mmHg) | 85.3 (9.7) | 80.7 (10.7) | 82.9 (10.5) |
| Fasting blood glucose (mmol/L) | 5.4 (1.5) | 5.2 (1.4) | 5.3 (1.5) |
| Serum triglyceride (mmol/L) | 1.6 (0.8) | 1.3 (0.7) | 1.4 (0.8) |
| Serum HDL-c (mmol/L) | 1.3 (0.3) | 1.6 (0.4) | 1.5 (0.4) |
| Serum LDL-c (mmol/L) | 3.2 (1.1) | 3.2 (1.0) | 3.2 (1.0) |
| Serum total cholesterol (mmol/L) | 5.2 (1.1) | 5.5 (1.0) | 5.4 (1.0) |
| HDL-c/LDL-c ratio | 4.2 (1.1) | 3.6 (1.1) | 3.9 (1.2) |
| Malay | 79 (41.6) | 90 (42.9) | 169 (42.3) |
| Chinese | 91 (47.9) | 102 (48.6) | 193 (48.3) |
| Indian or others | 20 (10.5) | 18 (8.6) | 38 (9.5) |
| Underweight | 16 (8.4) | 24 (11.4) | 40 (10.0) |
| Normal | 88 (46.3) | 95 (45.2) | 183 (45.8) |
| Overweight | 86 (45.3) | 91 (43.3) | 177 (44.3) |
| Sedentary | 80 (42.1) | 99 (47.1) | 179 (44.8) |
| Minimally active | 73 (38.4) | 85 (40.5) | 158 (39.5) |
| HEPA-active | 37 (19.5) | 26 (12.4) | 63 (15.8) |
| Yes | 78 (41.1) | 7 (3.3) | 85 (21.3) |
| No | 112 (58.9) | 203 (96.7) | 315 (78.8) |
| Yes | 65 (34.2) | 37 (17.6) | 102 (25.5) |
| No | 125 (65.8) | 173 (82.4) | 298 (74.5) |
| Yes | 137 (72.1) | 113 (53.8) | 150 (37.5) |
| No | 53 (27.9) | 97 (46.2) | 250 (62.5) |
| Osteoporosis (T-score ≤ -2.5) | 11 (5.8) | 38 (18.1) | 49 (12.3) |
| Osteopenia (T-score between -1 and -2.4) | 68 (35.8) | 101 (48.1) | 169 (42.3) |
| Normal (T-score > -1) | 111 (58.4) | 71 (33.8) | 182 (45.5) |
| Yes | 59 (31.1) | 149 (71.0) | 120 (30.0) |
| No | 131 (68.9) | 61 (29.0) | 280 (70.0) |
| Yes | 85 (44.7) | 127 (60.5) | 212 (53.0) |
| No | 105 (55.3) | 83 (39.5) | 188 (47.0) |
| Yes | 132 (69.5) | 109 (51.9) | 241 (60.2) |
| No | 58 (30.5) | 101 (48.1) | 159 (39.8) |
| Yes | 56 (29.5) | 44 (21.0) | 100 (25.0) |
| No | 134 (70.5) | 166 (79.0) | 300 (75.0) |
| Yes | 71 (37.4) | 56 (26.7) | 127 (31.8) |
| No | 119 (62.6) | 154 (73.3) | 273 (68.3) |
| Yes | 22 (11.6) | 44 (21.0) | 66 (16.5) |
| No | 168 (88.4) | 166 (79.0) | 334 (83.5) |
Notes: (1) increased waist circumference: ≥ 90 for men, ≥ 80 cm for women; (2) increased blood pressure: systolic blood pressure ≥ 130 mmHg and/or a diastolic pressure ≥ 85 mmHg, or the use of any anti-hypertensive agents; (3); increased fasting blood glucose: ≥ 5.5 mmol/L, or the use of any anti-diabetic agents; (4); increased: triglyceride level ≥ 1.7 mmol/L, or the use of any triglyceride-lowering agents (5); reduced HDL-c level: < 1.0 mmol/L in men, <1.3 mmol/L in women or the use of any agents to improve HDL-c level.
Bone mineral density of the subjects according to the status of metabolic syndrome
| No. of MetS component | Adjusted mean (SD) of spine BMD | Adjusted mean (SD) of hip BMD | ||||
|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 1 | Model 2 | Model 3 | |
| 0 (n=69) | 0.93 (0.16) | 0.93 (0.17) | 0.97 (0.17) | 0.85 (0.12) | 0.84 (0.12) | 0.89 (0.12) |
| 1 (n=99) | 0.91 (0.15) | 0.91 (0.16) | 0.93 (0.16) | 0.84 (0.12) | 0.84 (0.12) | 0.86 (0.11) |
| 2 (n=112) | 0.96 (0.16) | 0.95 (0.16) | 0.94 (0.15) | 0.89 (0.12)b | 0.89 (0.12) | 0.88 (0.11) |
| 3 (n=68) | 0.95 (0.16) | 0.95 (0.16) | 0.92 (0.16) | 0.89 (0.12) | 0.89 (0.12) | 0.86 (0.12) |
| 4 (n=41) | 1.03 (0.15)ab | 1.03 (0.15)ab | 1.00 (0.15) | 0.96 (0.12)abc | 0.96 (0.12)abc | 0.92 (0.12) |
| 5 (n=11) | 1.03 (0.15) | 1.00 (0.16) | 0.98 (0.15) | 0.88 (0.12) | 0.88 (0.12) | 0.86 (0.11) |
| 0.059 | 0.060 | |||||
| No (n=280) | 0.94 (0.15) | 0.93 (0.15) | 0.95 (0.15) | 0.86 (0.12) | 0.86 (0.12) | 0.87 (0.12) |
| Yes (n=120) | 0.98 (0.15) | 0.98 (0.15) | 0.96 (0.16) | 0.91 (0.12) | 0.91 (0.12) | 0.88 (0.12) |
| 0.625 | 0.478 | |||||
The letter 'a' indicates a significant difference (p<0.05) compared to '0 MetS component'; 'b' compared to '1 MetS component'; 'c' compared to '2 MetS components'. Model 1: adjusted for age, sex, ethnicity; Model 2: adjusted for Model 1 + physical activity status, cigarette-smoking status, alcohol-drinking status, dairy-consumption status; Model 3: adjusted for Model 2 + body mass index. Abbreviation: BMD, bone mineral density; MetS, metabolic syndrome; n, sample size; SD, standard deviation.
The relationship between metabolic syndrome/its components and bone mineral density
| Spine BMD | Hip BMD | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 1 | Model 2 | Model 3 | |||||||||||||
| β | 95 % CI | β | 95 % CI | β | 95 % CI | β | 95 % CI | β | 95 % CI | β | 95 % CI | |||||||
| Waist circumference | 0.153 | L: 0.039 | 0.149 | L: 0.003 | -0.183 | L: -0.361 | 0.234 | L: 0.134 | 0.219 | L: 0.076 | -0.179 | L: -0.330 | ||||||
| Systolic blood pressure | 0.07 | L: -0.080 | 0.359 | 0.095 | L: -0.091 | 0.223 | 0.043 | L: -0.107 | 0.577 | 0.158 | L: 0.026 | 0.168 | L: -0.161 | 0.114 | L: -0.013 U: 0.242 | 0.080 | ||
| Diastolic blood pressure | 0.048 | L: -0.099 | 0.525 | 0.029 | L: -0.010 | 0.702 | 0.018 | L: -0.127 | 0.808 | -0.092 | L: -0.222 | 0.165 | -0.099 | L: -0.293 | 0.134 | -0.092 | L: -0.215 | 0.147 |
| Fasting blood glucose | 0.039 | L: -0.060 | 0.437 | 0.011 | L: -0.075 | 0.833 | 0.006 | L: -0.093 | 0.904 | 0.062 | L: -0.025 | 0.166 | 0.037 | L: -0.050 | 0.413 | 0.013 | L: -0.071 | 0.759 |
| Serum triglyceride | -0.024 | L: -0.127 | 0.647 | -0.001 | L: -0.174 | 0.991 | -0.015 | L: -0.118 | 0.772 | 0.035 | L: -0.056 | 0.456 | 0.042 | L: -0.040 | 0.366 | 0.04 | L: -0.048 | 0.377 |
| Serum HDL-c | -0.009 | L: -0.128 | 0.877 | 0.001 | L: -0.050 | 0.981 | -0.007 | L: -0.127 | 0.905 | -0.038 | L: -0.143 | 0.473 | -0.048 | L: -0.153 | 0.378 | -0.035 | L: -0.137 | 0.497 |
| MetS | 0.127 | L: 0.035 | 0.128 | L: 0.035 | 0.009 | L: -0.097 | 0.851 | 0.163 | L: 0.078 | 0.165 | L: 0.081 | 0.006 | L: -0.079 | 0.896 | ||||
*the sample size is < 400 because multivariate outliers were removed. L: Lower 95% CI; U: Upper 95% CI. Model 1: adjusted for age, sex, ethnicity; Model 2: adjusted for Model 1 + physical activity status, cigarette-smoking status, alcohol-drinking status, dairy-consumption status; Model 3: adjusted for Model 2 + body mass index. Abbreviation: β, standardized regression coefficient; BMD, bone mineral density; HDL-c, high-density lipoprotein cholesterol; MetS, metabolic syndrome; n, sample size.
The relationship between metabolic syndrome/its components and osteoporosis
| Model 1 | Model 2 | Model 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | OR | 95% CI | ||||
| Waist circumference | 0.962 | 0.927-0.998 | 0.915 | 0.865-0.968 | 1.094 | 0.979-1.224 | 0.114 | ||
| Systolic blood pressure | 0.971 | 0.937-1.007 | 0.111 | 0.971 | 0.931-1.012 | 0.163 | 1.013 | 0.963-1.066 | 0.614 |
| Diastolic blood pressure | 1.032 | 0.972-1.097 | 0.304 | 1.020 | 0.950-1.094 | 0.589 | 0.938 | 0.842-1.044 | 0.242 |
| Fasting blood glucose | 0.947 | 0.716-1.252 | 0.701 | 0.853 | 0.584-1.245 | 0.409 | 1.066 | 0.618-1.838 | 0.819 |
| Serum triglyceride | 1.523 | 0.928-2.499 | 0.096 | 1.860 | 1.095-3.160 | 0.022 | 4.693 | 1.842-11.956 | |
| Serum HDL-c | 1.14 | 0.414-3.139 | 0.801 | 1.495 | 0.506-4.416 | 0.467 | 0.950 | 0.234-3.858 | 0.943 |
| n* | 396 | 386 | 382 | ||||||
| MetS | 0.209 | 0.057-0.770 | 0.545 | 0.221-1.346 | 0.188 | 0.907 | 0.186-4.411 | 0.904 | |
| n* | 380 | 391 | 383 | ||||||
*the sample size is < 400 because multivariate outliers were removed. Model 1: adjusted for age, sex, ethnicity; Model 2: adjusted for Model 1 + physical activity status, cigarette-smoking status, alcohol-drinking status, dairy-consumption status; Model 3: adjusted for Model 2 + body mass index. Abbreviation: CI, confidence interval; HDL-c, high-density lipoprotein cholesterol; MetS, metabolic syndrome; n, sample size; OR, odds ratio.